<DOC>
	<DOCNO>NCT00299364</DOCNO>
	<brief_summary>The benefit-risk-balance isopropanolic Cimicifuga racemosa extract ( iCR ) compare tibolone menopausal symptom treatment . Menopausal patient age 40 - 60 year Kupperman Menopause Index ( KMI ) equal 15 participate assign either iCR correspond 40 mg crude drug/day ( n=122 ) tibolone 2,5 mg/day ( n=122 ) orally . The primary endpoint benefit-risk balance end treatment .</brief_summary>
	<brief_title>Comparison Efficacy Tolerability Black Cohosh Vs Tibolone Patients With Menopausal Symptoms</brief_title>
	<detailed_description>The benefit-risk-balance isopropanolic Cimicifuga racemosa extract ( iCR ) compare tibolone menopausal symptom treatment . The randomized , double-blind , control 3-month study 5 centre 3 city China enrol 244 menopausal patient age 40 - 60 year Kupperman Menopause Index ( KMI ) equal 15 . The participant assign either iCR correspond 40 mg crude drug/day ( n=122 ) tibolone 2,5 mg/day ( n=122 ) orally . The primary endpoint combination Mann-Whitney value ( MWV ) KMI frequency adverse event ( benefit-risk balance ) end treatment .</detailed_description>
	<mesh_term>Tibolone</mesh_term>
	<criteria>40 year 60 year age spontaneous amenorrheic interval least 5 month since last regular menstruation patient amenorrheic interval less 12 month , baseline level E2 exceed 30 pg/ml Kupperman Menopause Index least 15 write informed consent good general health HRT last 4 week study entry treatment nonhormonal climacteric drug ( include TCM nutritional supplement ) use food interfere menopausal symptom last week study entry washout period first KMI evaluation treatment drug ( include phytotherapeutics ) ATC group N03 , N05 N06 last four week study entry washout period first KMI evaluation BMI &gt; 28 kg/m2 thickness uterine intima equal 5 mm ( patient amenorrhea 12 month longer ) 15 mm ( patient amenorrhea less 12 month ) irregular gynecological bleeding last 4 week start study medication without endometrial carcinoma rule cervical smear ( ASCUS ) express anything follow : intraepithelial pathologic change ( CIN1 , CIN2 , CIN3 , carcinoma situ ) , squamous carcinoma hysterectomy supracervical hysterectomy eight year amenorrhea contraindication tibolone cancer severe disease ( e.g . ... ) could mask climacteric complaint treatment could interfere study objective . For example , ... disease could influence baseline measurement KMI drug abuser , alcohol addict , etc . participation another clinical trial phase I , II last 180 day phase III , IV last 90 day study entry , simultaneous participation another clinical trial circumstance make investigator expect incomplete study participation patient</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Climacteric symptom</keyword>
	<keyword>Black Cohosh</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>